USOR 23292 - STAR Ph1/2a Study of ART0380 admin Mono + in Combo mSolid Tumors

A Phase I/IIa, Open-label, Multi-center Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the ATR Kinase Inhibitor ART0380 Administered Orally as Monotherapy and in Combination to Patients with Advanced or Metastatic Solid Tumors (ART0380C001)

Disease Types: Solid Tumor, STAR: Selected Trials Available for Accelerated Four Week Rollout

Available at: Arlington Heights, Niles